Phase 2 Study of MK-2206, an Allosteric Inhibitor of AKT, as Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer: A SWOG Cooperative Group Trial (S1005)

BACKGROUND: The AKT inhibitor MK-2206 at a dose of 60 mg every other day was evaluated in gastric/gastroesophageal junction cancers. METHODS: Patients who had progressed after first-line treatment were eligible. Pertinent eligibility criteria included adequate organ function, a fasting serum glucose...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer
Main Authors: Ramanathan, Ramesh K., McDonough, Shannon L., Kennecke, Hagen F., Iqbal, Syma, Baranda, Joaquina C., Seery, Tara E., Lim, Howard J., Hezel, Aram F., Vaccaro, Gina M., Blanke, Charles D.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4589423/
https://ncbi.nlm.nih.gov/pubmed/25827820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29363
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares